162 related articles for article (PubMed ID: 25395461)
1. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.
Ruan Y; Kovalchuk A; Jayanthan A; Lun X; Nagashima Y; Kovalchuk O; Wright JR; Pinto A; Kirton A; Anderson R; Narendran A
Neuro Oncol; 2015 Jun; 17(6):822-31. PubMed ID: 25395461
[TBL] [Abstract][Full Text] [Related]
2. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor.
Küsters-Vandevelde HV; Willemsen AE; Groenen PJ; Küsters B; Lammens M; Wesseling P; Djafarihamedani M; Rijntjes J; Delye H; Willemsen MA; van Herpen CM; Blokx WA
Acta Neuropathol Commun; 2014 Apr; 2():41. PubMed ID: 24713450
[TBL] [Abstract][Full Text] [Related]
3. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma.
Mitre V; Heym K; Clark GD; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e195-e197. PubMed ID: 31764519
[TBL] [Abstract][Full Text] [Related]
4. Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
Salgado CM; Basu D; Nikiforova M; Hamilton RL; Gehris R; Jakacki R; Panigrahy A; Yatsenko S; Reyes-Múgica M
Melanoma Res; 2015 Oct; 25(5):453-60. PubMed ID: 26266759
[TBL] [Abstract][Full Text] [Related]
5. Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases.
Uguen A; Laurent C; Samaison L; Boisselier B; Talagas M; Costa S; Aziza J; Mokhtari K; Le Maréchal C; Marcorelles P
Hum Pathol; 2015 Aug; 46(8):1189-96. PubMed ID: 26037215
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?
Patel J; Salgado CM; Múgica MR; Basu D
Neuro Oncol; 2016 Jan; 18(1):142-3. PubMed ID: 26667139
[No Abstract] [Full Text] [Related]
7. Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?".
Ruan Y; Narendran A
Neuro Oncol; 2016 Jan; 18(1):143-4. PubMed ID: 26667140
[No Abstract] [Full Text] [Related]
8. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.
Basu D; Salgado CM; Bauer BS; Johnson D; Rundell V; Nikiforova M; Khakoo Y; Gunwaldt LJ; Panigrahy A; Reyes-Múgica M
Neuro Oncol; 2016 Apr; 18(4):528-37. PubMed ID: 26354928
[TBL] [Abstract][Full Text] [Related]
9. Neurocutaneous melanocytosis (melanosis).
Ruggieri M; Polizzi A; Catanzaro S; Bianco ML; Praticò AD; Di Rocco C
Childs Nerv Syst; 2020 Oct; 36(10):2571-2596. PubMed ID: 33048248
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
11. Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience.
Lovett A; Maari C; Decarie JC; Marcoux D; McCuaig C; Hatami A; Savard P; Powell J
J Am Acad Dermatol; 2009 Nov; 61(5):766-74. PubMed ID: 19766348
[TBL] [Abstract][Full Text] [Related]
12. NRAS
Girolami I; Cima L; Ghimenton C; Zannoni M; Mombello A; Riva G; Cirielli V; Corradi G; Vogrig A; Di Stefano G; Novelli L; Gessi M; Eccher A
Brain Tumor Pathol; 2018 Oct; 35(4):217-223. PubMed ID: 30145692
[TBL] [Abstract][Full Text] [Related]
13. Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis.
Takahashi H; Natsumeda M; Hara N; Koyama A; Shimizu H; Miyashita A; Satake D; Mouri Y; Tsukano J; Kawabe K; Tsukamoto Y; Okada M; Ogura R; Yuki A; Umezu H; Kakita A; Ikeuchi T; Oishi M
Acta Neuropathol Commun; 2024 Jan; 12(1):14. PubMed ID: 38254245
[TBL] [Abstract][Full Text] [Related]
14. Making a mountain out of a molehill: NRAS, mosaicism, and large congenital nevi.
Gerami P; Paller AS
J Invest Dermatol; 2013 Sep; 133(9):2127-30. PubMed ID: 23949765
[TBL] [Abstract][Full Text] [Related]
15. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.
Kinsler VA; Thomas AC; Ishida M; Bulstrode NW; Loughlin S; Hing S; Chalker J; McKenzie K; Abu-Amero S; Slater O; Chanudet E; Palmer R; Morrogh D; Stanier P; Healy E; Sebire NJ; Moore GE
J Invest Dermatol; 2013 Sep; 133(9):2229-36. PubMed ID: 23392294
[TBL] [Abstract][Full Text] [Related]
16. Neurocutaneous melanosis presenting with hydrocephalus. Case report and review of the literature.
Acosta FL; Binder DK; Barkovich AJ; Frieden IJ; Gupta N
J Neurosurg; 2005 Jan; 102(1 Suppl):96-100. PubMed ID: 16206742
[TBL] [Abstract][Full Text] [Related]
17. A newborn with neurocutaneous melanocytosis and Dandy-Walker malformation.
De Cock J; Snauwaert J; Van Rompaey W; Morren MA; Demaerel P
Pediatr Neurol; 2014 Mar; 50(3):276-8. PubMed ID: 24321541
[TBL] [Abstract][Full Text] [Related]
18. Neurosurgical management of patients with neurocutaneous melanosis: a systematic review.
Rahman RK; Majmundar N; Ghani H; San A; Koirala M; Gajjar AA; Pappert A; Mazzola CA
Neurosurg Focus; 2022 May; 52(5):E8. PubMed ID: 35535823
[TBL] [Abstract][Full Text] [Related]
19. CSF cytology diagnosis of NRAS-mutated primary leptomeningeal melanomatosis with neurocutaneous melanosis.
Kolin DL; Geddie WR; Ko HM
Cytopathology; 2017 Jun; 28(3):235-238. PubMed ID: 27696542
[No Abstract] [Full Text] [Related]
20. Neurocutaneous melanosis: follow-up and literature review.
Scattolin MA; Lin J; Peruchi MM; Rocha AJ; Masruha MR; Vilanova LC
J Neuroradiol; 2011 Dec; 38(5):313-8. PubMed ID: 21489630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
